Company Summary

 
Attribute Description
Lpath is the category leader in lipidomic-based therapeutics Lpath's Founder helped pioneer the bioactive lipid signaling space, which, according recent articles in Nature Reviews (February 2008) and The British Journal of Cancer (October 2006), is an important emerging area of drug discovery. As such, we have deep and broad knowledge of lipids and how to work with them. Moreover, we have demonstrated a unique ability, using our ImmuneY2™ technology, to generate monoclonal antibodies against bioactive lipids, setting us apart from the rest of the field.
Powerful Pipeline Capability We used our proprietary ImmuneY2™ drug-discovery engine to develop the first ever monclonal antibodies against bioactive lipids. The first was Sphingomab™, whose systemic formulation is called ASONEP™ and whose ocular formulation is called iSONEP™; the second was Lpathomab™. With this ImmuneY2™ platform technology, we continue to generate novel antibodies against other bioactive-lipid targets, thus creating a compelling pipeline of therapeutic candidates.
Superior Intellectual Property Lpath has a total of over 35 issued or pending patents in the U.S. (with corresponding patent protection in Europe, Japan, etc.). Issued patent claims provide ownership of anti-sphingolipid therapeutic antibodies as compositions of matter; several patents issued and pending provide broad coverage of bioactive lipids as targets in the treatment of several diseases, including cancer, cardiovascular diseases, inflammation, autoimmune disorders, ocular disease and pathogenic angiogenesis. Because Lpath is a pioneer in the field, many of these issued and allowed patents may be considered dominating.
Experienced Executive & Advisory Team Roger Sabbadini, Ph.D., Founder and CSO: pioneer in bioactive lipid research; his lab has been studying the role of sphingolipid mediators in disease states for over 17 years.
Scott Pancoast, CEO: Harvard MBA, broad management/CEO experience; venture capitalist for 11 years with focus on biotechs.
Gary Atkinson, CFO: over 25 years experience in corporate finance and accounting for public and private companies.
Glenn Stoller, M.D., Head of Lpath Ocular: practicing retinal-eye surgeon; former advisor to Genentech and OSI/Eyetech.
 
We also utilize the services of several world-class consultants and SAB members with expertise in research, oncology, ophthalmology, inflammation, cardiology and diagnostics.